A randomized, controlled trial for risk factor reduction in patients with symptomatic vascular disease: The multidisciplinary Vascular Prevention by Nurses Study (VENUS)

European Journal of Preventive Cardiology

Volumn 13, Issue 6, 2006, Pages 996-1003

  Goessens, Bertine M B ^a   Visseren, Frank L J ^a   Sol, Berna G M ^a   de Man Van Ginkel, Janneke M ^a   Van Der Graaf, Yolanda ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

cardiovascular disease; nurse practitioner; risk factors; secondary prevention

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG USE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEALTH CARE QUALITY; HIGH RISK PATIENT; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; NURSE PRACTITIONER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION; SMOKING; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; AGED; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; INTERVENTION STUDIES; LOGISTIC MODELS; MALE; MIDDLE AGED; NETHERLANDS; NURSE PRACTITIONERS; PATIENT COMPLIANCE; RISK FACTORS; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME; VASCULAR DISEASES;

EID: 33845447458     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/01.hjr.0000216549.92184.40     Document Type: Article

References (39)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997; 349: 1498–1504.
2. Kannel WB. Overview of atherosclerosis Clin Ther 1998; 20 (Suppl B):B2–B17.
3. DeBacker G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 1601–1610.
4. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997; 18: 1569–1582.
5. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001; 357: 995–1001.
6. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554–572.
7. Erhardt LR. Barriers to effective implementation of guideline recommendations Am J Med 2005; 118(Suppl 12A):36–41.
8. Mosca L, Linfante AH, Benjamin EJ, Berra K, Hayes SN, Walsh BW, et al National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation 2005; 111: 499–510.
9. Sol BG, Van der Bijl JJ, Banga JD, Visseren FL. Vascular risk management through nurse-led self-management programs. J Vasc Nurs 2005; 23: 20–24.
10. Allen JK, Blumenthal RS, Margolis S, Young DR, Miller ER III, Kelly K. Nurse case management of hypercholesterolemia in patients with coronary heart disease: results of a randomized clinical trial. Am Heart J 2002; 144: 678–686.
11. Campbell NC, Ritchie LD, Thain J, Deans HG, Rawles JM, Squair JL. Secondary prevention in coronary heart disease: a randomised trial of nurse led clinics in primary care. Heart 1998; 80: 447–452.
12. Carlsson R, Lindberg G, Westin L, Israelsson B. Influence of coronary nursing management follow up on lifestyle after acute myocardial infarction. Heart 1997; 77: 256–259.
13. Cupples ME, McKnight A. Randomised controlled trial of health promotion in general practice for patients at high cardiovascular risk. BMJ 1994; 309: 993–996.
14. Cupples ME, McKnight A. Five year follow up of patients at high cardiovascular risk who took part in randomised controlled trial of health promotion. BMJ 1999; 319: 687–688.
15. Jolly K, Bradley F, Sharp S, Smith H, Thompson S, Kinmonth AL, et al Randomised controlled trial of follow up care in general practice of patients with myocardial infarction and angina: final results of the Southampton heart integrated care project (SHIP). The SHIP Collaborative Group. BMJ 1999; 318: 706–711.
16. McHugh F, Lindsay GM, Hanlon P, Hutton I, Brown MR, Morrison C, et al Nurse led shared care for patients on the waiting list for coronary artery bypass surgery: a randomised controlled trial. Heart 2001; 86: 317–323.
17. Murchie P, Campbell NC, Ritchie LD, Simpson JA, Thain J. Secondary prevention clinics for coronary heart disease: four year follow up of a randomised controlled trial in primary care. BMJ 2003; 326: 84.
18. Quist-Paulsen P, Gallefoss F. Randomised controlled trial of smoking cessation intervention after admission for coronary heart disease. BMJ 2003; 327: 1254–1257.
19. Vale MJ, Jelinek MV, Best JD, Dart AM, Grigg LE, Hare DL, et al Coaching patients On Achieving Cardiovascular Health (COACH): a multicenter randomized trial in patients with coronary heart disease. Arch Intern Med 2003; 163: 2775–2783.
20. Ellis G, Rodger J, McAlpine C, Langhorne P. The impact of stroke nurse specialist input on risk factor modification: a randomised controlled trial. Age Ageing 2005; 34: 389–392.
21. Zelen M. A new design for randomized clinical trials. N Engl J Med 1979; 300: 1242–1245.
22. Bamford JM, Sandercock PA, Warlow CP, Slattery J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1989; 20: 828.
23. Simons PC, Algra A, van de Laak MF, Grobbee DE, van der Graaf Y. Second manifestations of ARTerial disease (SMART) study: rationale and design. Eur J Epidemiol 1999; 15: 773–781.
24. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.
25. World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983–1992.
26. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26(Suppl 1):S5–S20.
27. Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost 1999; 81: 165–176.
28. Kang SS, Wong PW, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr 1992; 12: 279–298.
29. World Health Organization (WHO). Obesity: preventing and managing the global epidemic. Geneva: World Health Organization; 2004.
30. Goldstein MG, Niaura R. Methods to enhance smoking cessation after myocardial infarction. Med Clin North Am 2000; 84: 63viii–80viii.
31. Raw M, McNeill A, West R. Smoking cessation: evidence based recommendations for the healthcare system. BMJ 1999; 318: 182–185.
32. Ware JE Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473–483.
33. McAlister FA, Lawson FM, Teo KK, Armstrong PW. Randomised trials of secondary prevention programmes in coronary heart disease: systematic review. BMJ 2001; 323: 957–962.
34. van Wyk JT, van Wijk MA, Sturkenboom MC, Moorman PW, van der LJ. Identification of the four conventional cardiovascular disease risk factors by Dutch general practitioners. Chest 2005; 128: 2521–2527.
35. Riley J. The nurse as expert practitioner in global cardiovascular risk management Heart 2003; 89 (Suppl 2):ii33–ii34.
36. Raftery JP, Yao GL, Murchie P, Campbell NC, Ritchie LD. Cost effectiveness of nurse led secondary prevention clinics for coronary heart disease in primary care: follow up of a randomised controlled trial. BMJ 2005; 330: 707.
37. Homer CS. Using the Zelen design in randomized controlled trials: debates and controversies. J Adv Nurs 2002; 38: 200–207.
38. Schellings R, Kessels AG, ter Riet G, Sturmans F. The Zelen design may be the best choice for a heroin-provision experiment. J Clin Epidemiol 1999; 52: 503–507.
39. Klungel OH, de Boer A, Paes AH, Herings RM, Seidell JC, Bakker A. Influence of question structure on the recall of self-reported drug use. J Clin Epidemiol 2000; 53: 273–277.